Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/Azathioprine

Next Previous
Trial Profile

A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/Azathioprine

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avacopan (Primary) ; Azathioprine; Cyclophosphamide; Cyclophosphamide; Mycophenolate; Prednisone; Rituximab
  • Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Granulomatosis with polyangiitis; Microscopic polyangiitis
  • Focus Registrational; Therapeutic Use
  • Acronyms ADVOCATE
  • Sponsors ChemoCentryx

Most Recent Events

  • 12 Jun 2024 According to an Amgen media release, the company announced the presentation of data of this trial at the European Alliance of Associations for Rheumatology's (EULAR) 2024 Congress, June 12-15 in Vienna.
  • 01 May 2024 According to an Amgen media release, results of a post-hoc analysis from this trial will be presented at the American Thoracic Society (ATS) 2024 International Conference taking place May 12-22 in San Diego.
  • 18 Nov 2023 Results of subgroup analysis assessing the safety and efficacy of Avacopan in patients with ANCA-associated vasculitis receiving rituximab published in the Annals of the Rheumatic Diseases.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top